Noncoding RNAs in gastric cancer: implications for drug resistance

Wei, Ling; Sun, Jian; Zhang, Nasha; Zheng, Yan; Wang, Xin; Lv, Li; Liu, Jiandong; Xu, Yeyang; Shen, Yue; Yang, Ming

doi:10.1186/s12943-020-01185-7

Cited by 317 publications

(273 citation statements)

References 196 publications

Supporting

Mentioning

262

Contrasting

Order By: Relevance

“…Various small ncRNA vectors or systems have been proposed and widely explored for this purpose, including nanoparticles, ncRNA modification, and oncolytic adenovirus strategies. Nanoparticle-based small ncRNA vectors are the most common strategy [ 89 ]. SNHG3 is located in the nucleus and cytoplasm and requires a carrier to transport antisense RNAs or siRNAs into the cell to function [ 90 ].…”

Section: Perspectives In Clinical Practicementioning

confidence: 99%

LncRNA SNHG3, a potential oncogene in human cancers

Mei

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are composed of > 200 nucleotides; they lack the ability to encode proteins but play important roles in a variety of human tumors. A large number of studies have shown that dysregulated expression of lncRNAs is related to tumor oncogenesis and progression. Emerging evidence shows that SNHG3 is a novel oncogenic lncRNA that is abnormally expressed in various tumors, including osteosarcoma, liver cancer, lung cancer, etc. SNHG3 primarily competes as a competitive endogenous RNA (ceRNA) that targets tumor suppressor microRNAs (miRNAs) and ceRNA mechanisms that regulate biological processes of tumors. In addition, abnormal expression of SNHG3 is significantly correlated with patient clinical features. Upregulation of SNHG3 contributes to biological functions, including tumor cell proliferation, migration, invasion and EMT. Therefore, SNHG3 may represent a potential diagnostic and prognostic biomarker, as well as a novel therapeutic target.

show abstract

Section: Perspectives In Clinical Practicementioning

confidence: 99%

LncRNA SNHG3, a potential oncogene in human cancers

Mei

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…LncRNAs have been reported to play essential roles in drug resistance in multiple cancers, such as breast cancer (16), gastric cancer (17), and lung cancer (18). For example, lnc-ATB/miR-200c promoted resistance to trastuzumab and then induced an invasion-metastasis cascade in breast cancer via upregulating ZEB1 and ZNF-217 (19).…”

Section: Discussionmentioning

confidence: 99%

LncRNA BANCR Attenuates the Killing Capacity of Cisplatin on Gastric Cancer Cell through the ERK1/2 Pathway

Xiang

Liu

Fan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Chemotherapy-based comprehensive treatment is the most important therapeutic method for patients with advanced gastric cancer, but chemoresistance often causes treatment failure. Long non-coding RNA (LncRNA) BRAF-activated non-coding RNA (BANCR) has been shown to participate in many biological behaviors of multiple cancers. However, the biological roles of LncRNA BANCR in chemoresistance of gastric cancer remain unclear. Here, we aimed to evaluate the functions of LncRNA BANCR in the therapy of gastric cancer. Methods In this study, LncRNA BANCR expression was detected in GC patient samples and cell lines by quantity polymerase chain reaction (qPCR). Cell proliferation and viability in cisplatin treated cells were measured using clonogenic survival assay and cell counting kit-8. The levels of ERK1/2 pathway molecules were tested with western blot. Ly3214996, an inhibitor of ERK signal pathway, administration was used to assess the effects of BANCR overexpression on GC cell cisplatin-treated resistance. Moreover, the role of BANCR in cisplatin resistance of GC was certified in xenograft mouse models in vivo. Results our study showed that LncRNA BANCR expression was also significantly increased in GC tissues compared with adjacent normal tissues. Furthermore, we found that BANCR overexpression promoted, while BANCR inhibited, GC cell resistance to cisplatin in vitro. Ly3214996 treatment abolished the BANCR overexpression-mediated GC cell cisplatin resistance via regulating the phosphorylation of ERK protein. Knock-down of BANCR delayed significantly tumor growth in xenograft mouse models. Conclusion BANCR promoted cisplatin resistance of GC cells by activating ERK1/2 pathway. Inhibition of BANCR was markedly suppressed the growth of gastric cancer cells in vitro as well as in vivo. This result provided a new strategy for gastric cancer via targeting BANCR

show abstract

“…lncRNAs, circRNAs, and miRNAs are critical in tumorigenesis and may serve as promising therapeutic targets and biomarkers for cancers [ 9 , 173 , 174 ]. ceRNAs communicate with different types of RNAs in cancer progression, forming the network among lncRNAs, circRNAs, miRNAs, and mRNAs [ 15 , 131 ].…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

“…Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are non-coding RNAs (ncRNAs) with respective lengths of more than 200 nucleotides and about 22 nucleotides. Both participate in various physiological and pathological processes involving tumorigenesis, such as cell proliferation, apoptosis, EMT, invasion, migration, chemoresistance, and stemness [ 9 ]. lncRNAs can regulate gene expression through repressing chromatin components [ 10 ], mediating epigenetic silencing, interacting with Polycomb complex, and modulating transcription activation [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

The Roles of ceRNAs-Mediated Autophagy in Cancer Chemoresistance and Metastasis

Zhang

Lü

2020

Cancers

View full text Add to dashboard Cite

Chemoresistance and metastasis are the main causes of treatment failure and unfavorable outcome in cancers. There is a pressing need to reveal their mechanisms and to discover novel therapy targets. Autophagy is composed of a cascade of steps controlled by different autophagy-related genes (ATGs). Accumulating evidence suggests that dysregulated autophagy contributes to chemoresistance and metastasis via competing endogenous RNA (ceRNA) networks including lncRNAs and circRNAs. ceRNAs sequester the targeted miRNA expression to indirectly upregulate ATGs expression, and thereof participate in autophagy-mediated chemoresistance and metastasis. Here, we attempt to summarize the roles of ceRNAs in cancer chemoresistance and metastasis through autophagy regulation.

show abstract

Noncoding RNAs in gastric cancer: implications for drug resistance

Cited by 317 publications

References 196 publications

LncRNA SNHG3, a potential oncogene in human cancers

LncRNA SNHG3, a potential oncogene in human cancers

LncRNA BANCR Attenuates the Killing Capacity of Cisplatin on Gastric Cancer Cell through the ERK1/2 Pathway

The Roles of ceRNAs-Mediated Autophagy in Cancer Chemoresistance and Metastasis

Contact Info

Product

Resources

About